Magnesium-Assisted Cisplatin Inhibits Bladder Cancer Cell Survival by Modulating Wnt/β-Catenin Signaling Pathway

Tianye Li, Zihan Tang, Chunting Li, Xiaoya Liu, Linglin Cheng, Zhijing Yang, Xiaojin Zhu, Weiwei Liu, Yongye HuangFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates how magnesium can enhance the effectiveness of cisplatin, a common chemotherapy drug for bladder cancer. Researchers found that combining magnesium chloride (MgCl₂) with cisplatin significantly reduced bladder cancer cell survival and increased apoptosis. This synergistic effect appears to be mediated by magnesium's ability to further downregulate the Wnt/β-catenin signaling pathway, a key player in cancer progression.

What Problem Does This Paper Address?

Cisplatin is a cornerstone in bladder cancer treatment, but its efficacy is often hampered by drug resistance and significant side effects. This creates a need for strategies to improve cisplatin's therapeutic index – making it more potent against cancer cells while minimizing harm to healthy tissues. Previous research has hinted at magnesium's role in cellular processes, and this study aims to explore whether magnesium can act as an adjuvant to boost cisplatin's anti-cancer activity, specifically by targeting the Wnt/β-catenin signaling pathway, which is frequently dysregulated in cancer.

Methods

The researchers employed a multi-pronged approach to assess the effects of magnesium and cisplatin on bladder cancer cells:

  • Cell Viability Assays (CCK-8): Standard assays were used to quantify the survival rates of bladder cancer cells (UC3 and UC5) under various treatment conditions.
  • Colony Formation Assay: This technique assessed the long-term proliferative capacity of cancer cells after treatment, indicating their ability to form colonies.
  • Propidium Iodide (PI) Staining: Used to identify and quantify dead cells, providing a measure of cell death.
  • Annexin V-FITC/PI Staining (Flow Cytometry): A more detailed method to distinguish between apoptotic (programmed cell death) and necrotic cells.
  • Quantitative Polymerase Chain Reaction (qPCR): Used to measure the mRNA expression levels of key genes involved in apoptosis, cell cycle regulation, and signaling pathways.
  • Western Blot Analysis: Employed to detect and quantify protein levels, providing insights into the molecular mechanisms of the treatments. This included assessing proteins related to apoptosis, cell cycle, autophagy, ER stress, and the Wnt/β-catenin pathway.
  • Nuclear and Cytoplasmic Protein Extraction: This technique allowed for the specific analysis of β-catenin localization, distinguishing between its presence in the cytoplasm and nucleus.
  • Immunofluorescence Microscopy: Used to visualize the cellular localization of β-catenin, confirming western blot findings.
  • Transwell Assay: A standard method to evaluate cell migration, crucial for understanding metastasis.
  • Wnt/β-Catenin Pathway Modulation: The study used 6-bromoindirubin-3'-oxime (BIO), a known activator of the Wnt/β-catenin pathway, to probe the role of this pathway in magnesium's effects.

Datasets

Not discussed in the paper. The study utilized established human bladder cancer cell lines (UM-UC3, UM-UC5) and HEK 293 cells for their experiments.

Key Insights and Ideas

  • Magnesium as a Cisplatin Potentiator: The most striking finding is that magnesium isn't just a bystander; it actively enhances cisplatin's ability to kill bladder cancer cells. This suggests a potential for novel combination therapies.
  • Wnt/β-Catenin Pathway as a Key Target: The study strongly implicates the Wnt/β-catenin pathway as a central mediator of magnesium's effects. Magnesium appears to suppress this pathway, which is often hyperactive in cancer, leading to reduced cell survival.
  • Dual Role of Magnesium: Magnesium seems to influence multiple cellular processes, including apoptosis, autophagy, and ER stress, contributing to its anti-cancer effects.
  • Precise Regulation is Key: The experiments with BIO suggest that while activating the Wnt/β-catenin pathway can enhance cell death, the moderate downregulation by magnesium is crucial for its synergistic effect with cisplatin. Over-activation of the pathway might have different outcomes.

Key Results

  • Reduced Cell Survival: Combinatorial treatment with MgCl₂ and cisplatin significantly decreased the survival rate of UC3 and UC5 bladder cancer cells compared to either agent alone. For UC3 cells, survival dropped from ~51.6% with cisplatin alone to ~38.5% with the combination.
  • Increased Apoptosis: The proportion of apoptotic cells was significantly higher in cells treated with both MgCl₂ and cisplatin.
  • Downregulation of Nuclear β-catenin: Cisplatin treatment led to a decrease in nuclear β-catenin, and MgCl₂ further reduced its nuclear localization. This is a critical finding, as nuclear β-catenin is a driver of cancer cell proliferation.
  • Modulation of Apoptosis-Related Genes: The expression of pro-apoptotic genes (e.g., Bax, Bid) was increased, while anti-apoptotic genes (e.g., Bcl-2) were modulated, favoring cell death.
  • Suppressed Cell Migration: The transwell assay showed that MgCl₂ and cisplatin combined significantly reduced the migration of UC3 cells, suggesting a potential impact on metastasis.
  • Autophagy Induction: The expression of LC3-II, a marker of autophagy, was upregulated by the combined treatment, indicating that autophagy was induced.

Limitations and Future Work

  • In Vitro Study: The findings are based on cell culture experiments. Further validation in animal models and eventually human clinical trials is necessary to confirm these results.
  • Mechanism Nuances: While the Wnt/β-catenin pathway is highlighted, the precise interplay between magnesium, cisplatin, and other cellular processes like autophagy and ER stress requires deeper investigation.
  • Optimal Dosage and Timing: The study explored various concentrations, but further optimization of the MgCl₂ and cisplatin dosage and treatment schedule could yield even better results.
  • Specific Bladder Cancer Subtypes: The study focused on UC3 and UC5 cell lines. Investigating the effects across a broader range of bladder cancer subtypes would be beneficial.
  • Clinical Translation: The authors suggest that the precise regulation of the Wnt/β-catenin signaling pathway is key for enhancing magnesium-based cancer therapy, implying that future research should focus on developing strategies for this fine-tuning in a clinical setting.

Summary updated

Abstract

Magnesium, an essential mineral micronutrient, plays a role in the activation of various transporters and enzymes. The present study aimed to investigate the possibility of applying magnesium to enhance the efficacy of cisplatin which is still ranked as one of the major chemotherapeutic drugs for bladder cancer patients. Results showed that the survival rate and colony formation of bladder cancer cells were reduced by combinatorial treatment with cisplatin and magnesium chloride (MgCl<sub>2</sub>). The proportion of apoptotic cells was also increased in UC3 bladder cancer cells treated with a combination of cisplatin and MgCl<sub>2</sub>. Most importantly, a marked decrease in nuclear β-catenin was observed in cells that received cisplatin treatment. In addition, the nuclear β-catenin in cisplatin treated cells was further down-regulated by supplementing MgCl<sub>2</sub>. 6-bromoindirubin-3'-oxime (BIO), an inhibitor of glycogen synthase kinase-3 (GSK-3) that activates the Wnt/β-catenin signaling pathway by modulating β-catenin activity, was thus applied to further exploit the role of this signaling pathway in magnesium aided cancer treatment. The survival rate of bladder cancer cells was decreased by BIO treatment at concentrations of 1.0, 2.5 and 5.0 μM accompanied by increased β-catenin expression. However, the expression of β-catenin in MgCl<sub>2</sub>-treated cells was lower than in untreated cells under the same BIO concentration. The expression of cleaved caspase-3, cleaved caspase-9 and microtubule-associated protein 1 light chain 3- II (LC3-II) was highest in cells treated with MgCl<sub>2</sub> and 5.0 μM BIO among the examined groups. Our findings reveal that magnesium could contribute to cisplatin-based chemotherapy by moderately regulating the Wnt/β-catenin signaling pathway.
BibTeX
@inproceedings{li2022magnesium,
  author = {Tianye Li and Zihan Tang and Chunting Li and Xiaoya Liu and Linglin Cheng and Zhijing Yang and Xiaojin Zhu and Weiwei Liu and Yongye Huang},
  title = {{Magnesium-Assisted Cisplatin Inhibits Bladder Cancer Cell Survival by Modulating Wnt/β-Catenin Signaling Pathway}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2021.804615},
}
Figure